Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

An Investigational New Drug (IND) is a drug or biological drug that has not been approved for general use by the FDA. It is used in a clinical trial to investigate its safety and efficacy. The term ...

The company has already had a discussion with the FDA to pursue an investigational new drug (IND) application for NRC.

(RTTNews) - Olema Pharmaceuticals (OLMA) announced the FDA has cleared Investigational New Drug application for OP-3136, a small molecule that potently and selectively inhibits KAT6, a validated ...

The "bio-bucks" deal gives the company up to $20 million in upfront and research payouts initially. From the San Francisco ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OP-3136, a novel small molecule that potently and selectively ...

In spring 2024, CBER reported more than 70 investigational new drug applications (IND) that involved artificial intelligence (AI) or machine learning (ML) in some way. “We have seen remarkable p ...

Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.